INR 1764.95
(0.06%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 3.72 Billion INR | 8257.65% |
2022 | 44.53 Million INR | -6.11% |
2021 | 47.43 Million INR | -5.05% |
2020 | 49.95 Million INR | -16.9% |
2019 | 60.11 Million INR | -9.35% |
2018 | 66.31 Million INR | -7.1% |
2017 | 71.38 Million INR | 11.95% |
2016 | 63.76 Million INR | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q1 | - INR | -100.0% |
2024 Q2 | 2.94 Billion INR | 0.0% |
2023 Q3 | - INR | -100.0% |
2023 FY | 3.72 Billion INR | 8257.65% |
2023 Q2 | 3.57 Billion INR | 0.0% |
2023 Q1 | - INR | -100.0% |
2023 Q4 | 3.72 Billion INR | 0.0% |
2022 Q1 | - INR | -100.0% |
2022 Q2 | 45.44 Million INR | 0.0% |
2022 Q4 | 44.53 Million INR | 0.0% |
2022 FY | 44.53 Million INR | -6.11% |
2022 Q3 | - INR | -100.0% |
2021 Q1 | - INR | -100.0% |
2021 FY | 47.43 Million INR | -5.05% |
2021 Q3 | - INR | -100.0% |
2021 Q2 | 47.93 Million INR | 0.0% |
2021 Q4 | 47.43 Million INR | 0.0% |
2020 Q4 | 49.95 Million INR | 0.0% |
2020 Q1 | 59.87 Million INR | -0.4% |
2020 FY | 49.95 Million INR | -16.9% |
2019 FY | 60.11 Million INR | -9.35% |
2019 Q4 | 60.11 Million INR | 0.0% |
2019 Q1 | - INR | 0.0% |
2018 FY | 66.31 Million INR | -7.1% |
2017 FY | 71.38 Million INR | 11.95% |
2016 FY | 63.76 Million INR | 0.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
Abbott India Limited | 832.3 Million INR | -347.154% |
Cipla Limited | 5.59 Billion INR | 33.472% |
GlaxoSmithKline Pharmaceuticals Limited | 186.65 Million INR | -1893.924% |
Kopran Limited | 992.28 Million INR | -275.06% |
Marksans Pharma Limited | 2.44 Billion INR | -52.489% |
NGL Fine-Chem Limited | 324.42 Million INR | -1047.159% |
Pfizer Limited | 945.4 Million INR | -293.66% |
Sanofi India Limited | 190 Million INR | -1858.768% |
SMS Pharmaceuticals Limited | 2.8 Billion INR | -32.552% |
TTK Healthcare Limited | 228.1 Million INR | -1531.548% |